First-in-Class Oral IL-23 Receptor Blocker Icotrokinra Achieves 65% Skin Clearance in Phase 3 Psoriasis Trial
<p>A phase 3 clinical trial published in the New England Journal of Medicine found that icotrokinra, the first oral peptide to selectively b...
View »